ECO ANIMAL HEALTH GROUP PLC

AGM Information • Aug 21, 2025

National Storage Mechanism | Additional information

RNS Number : 3038W

Eco Animal Health Group PLC

21 August 2025

21 August 2025

ECO Animal Health Group plc

("ECO" or the "Company")

Result of General Meeting

ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, announces that at a General Meeting held earlier today, the single special resolution proposed was duly passed.

As a result, trustees of the ECO Animal Health Group Employee Benefit Trust will shortly commence limited on-market purchases of the Company's ordinary shares of 5 pence each.

Voting results from the General Meeting will be made available on the Company's website at https://ecoanimalhealth.com/investors/ .

-Ends-

Contacts

ECO Animal Health Group plc David Hallas (Chief Executive Officer) Christopher Wilks (Chief Financial Officer)	020 8447 8899
ICR Healthcare (Financial PR) Mary-Jane Elliott Jessica Hodgson	020 3709 5700
Singer Capital Markets (Nominated Adviser & Joint Broker) Philip Davies Sam Butcher	020 7496 3000
Investec (Joint Broker) Gary Clarence Lydia Zychowska	020 7597 5970
Equity Development Hannah Crowe Matt Evans	020 7065 2692

About ECO Animal Health

ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.

Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.

Our lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry.

Click here for more information: https://ecoanimalhealth.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ROMFFLFLEVLLBBV